$240.00
Juvederm® Volux Lidocaine Dermal Filler Formulated with 25mg/ml VYCROSS™ 2.0 HA and integrated pain-reduction technology, it delivers sculpted results lasting up to 24 months. and, this professional-grade formula combines 98% pure hyaluronic acid with collagen-stimulating properties for safe, precision enhancement.
Juvederm Volux (VYC-25L) is Allergan’s highest-density Vycross filler — 25 mg/mL cross-linked HA + 0.3% lidocaine with the highest G’ (elastic modulus) and cohesivity in the Vycross range. The first-and-only FDA-approved filler for jawline definition. Engineered for deep subcutaneous and supraperiosteal placement: chin projection, jawline contouring. 18-24 months durability.
Allergan / AbbVie’s proprietary cross-linking process produces a stabilised HA gel matrix engineered for sustained tissue retention. The technology balances viscoelasticity (firmness for projection) with extrusion smoothness (easier injection through the 27G needle). The result: predictable handling, consistent gel distribution, and 18-24 months durability in deep subcutaneous placement.
Non-animal hyaluronic acid produced by bacterial fermentation. Endotoxin levels controlled below international safety thresholds. Stringent manufacturing under GMP-certified conditions minimises BDDE residue, heavy metals, and protein contaminants — reducing the risk of post-injection inflammation, granuloma formation, or hypersensitivity reactions in suitable patient profiles.
Non-animal hyaluronic acid produced by bacterial fermentation, cross-linked using Allergan / AbbVie’s Patented Vycross Cross-Linking Technology (VYC-25L) technology. The cross-linking process creates a stable, durable gel matrix that resists rapid enzymatic breakdown in tissue. Phosphate-buffered saline carries the gel at near-physiological pH.
Premixed local anaesthetic at the industry-standard 0.3% concentration. Reduces injection-site discomfort and eliminates the need for on-site mixing with separate lidocaine vials. The lidocaine itself wears off within hours of injection and does not affect long-term gel duration.
Primary FDA-approved indication. Deep subcutaneous placement for moderate-to-severe loss of jawline definition. The first-and-only FDA-approved filler for this indication.
Non-surgical chin projection and profile enhancement. Supraperiosteal placement standard.
Gonial angle definition for face shape modification. The high G’ supports angular structure.
Overall lower-third facial sculpting. Often combined with Voluma in upper face for global rejuvenation.
| Feature | Juvederm | Juvederm (Allergan) | Restylane (Galderma) |
|---|---|---|---|
| HA Concentration | 25 mg/mL | 15–24 mg/mL | 20 mg/mL |
| Cross-Linking Tech | Vycross | Vycross / Hylacross | NASHA® / OBT |
| Lidocaine | 0.3% (premixed) | 0.3% (XC lines) | 0.3% (Lidocaine variants) |
| Duration | 18-24 months | 6–24 months (varies) | 6–18 months (varies) |
| Origin | France (Allergan / AbbVie) | USA (Allergan / AbbVie) | Sweden (Galderma) |
| Established Since | 1948 | 2006 | 1996 |
↔ Swipe horizontally on mobile to view all columns
Comparison based on manufacturer published data. See our top dermal filler comparison guide for broader market context.
Verify regulatory status at the official Korean MFDS database — nedrug.mfds.go.kr. For market pricing context, see our dermal filler pricing guide.
Juvederm Volux (VYC-25L) is Allergan’s highest-density Vycross filler — 25 mg/mL cross-linked HA + 0.3% lidocaine with the highest G’ (elastic modulus) and cohesivity in the Vycross range. The first-and-only FDA-approved filler for jawline definition. Engineered for deep subcutaneous and supraperiosteal placement: chin projection, jawline contouring. 18-24 months durability.
Juvederm Volux with Lidocaine is manufactured by Allergan / AbbVie, a France-based medical device and pharmaceutical company established in 1948. The product is part of the Juvederm dermal filler range, which is distributed across multiple international markets. Regulatory status: CE 0459 · FDA approved (first-and-only FDA jawline indication).
Juvederm Volux with Lidocaine contains 25 mg/mL of cross-linked hyaluronic acid plus 0.3% (3 mg/mL) premixed lidocaine for injection comfort. The hyaluronic acid is non-animal, produced by bacterial fermentation and cross-linked using Allergan / AbbVie’s Patented Vycross Cross-Linking Technology (VYC-25L) technology. Phosphate-buffered saline at near-physiological pH carries the gel.
Per Allergan / AbbVie’s clinical data, Juvederm Volux with Lidocaine delivers 18-24 months of correction depending on placement and patient factors. Duration depends on injection depth, dose, anatomical site, patient metabolism, and facial movement intensity. Deep subcutaneous placement typically delivers the longer end of the duration range.
Juvederm Volux with Lidocaine is engineered for deep subcutaneous · supraperiosteal placement. The standard recommended needle is 27G, supplied in the syringe blister pack. Some practitioners prefer a blunt-tip cannula of equivalent gauge for safer placement in highly vascular zones, particularly for deeper subcutaneous work.
Juvederm Volux with Lidocaine regulatory status: CE 0459 · FDA approved (first-and-only FDA jawline indication). The product’s KFDA registration in South Korea is the primary regulatory baseline. CE marking and other international approvals enable distribution in the EU and other regulated markets. US FDA status varies — buyers in regulated jurisdictions should verify approval scope before importation and clinical use.
Store Juvederm Volux with Lidocaine between 2 °C and 25 °C in original packaging, away from direct sunlight. Do not freeze — freezing damages the HA gel structure. Shelf life is typically 24 months from the manufacturing date printed on the box when unopened. Once a syringe is opened, contents must be used immediately. Partial syringes cannot be retained for later use due to sterility risk.
No. Juvederm Volux with Lidocaine uses non-animal hyaluronic acid produced by bacterial fermentation — the standard manufacturing approach for modern HA dermal fillers. The product contains no animal proteins or by-products, making it suitable for patients who avoid animal-derived medical products. The product is contraindicated in patients with severe allergies to gram-positive bacterial proteins (used in HA fermentation).
Yes — layered protocols combining different fillers are standard aesthetic practice. Juvederm Volux with Lidocaine can be combined with other Korean or international HA fillers, neuromodulators (botulinum toxin), or biostimulators (PLLA, calcium hydroxylapatite) within a single session. Always wait the recommended interval between different injectable products and confirm biocompatibility per each manufacturer’s IFU.
Volux (VYC-25L) was specifically engineered with 25 mg/mL HA — the highest in the Vycross range — to maximise G’ (elastic modulus, resistance to deformation) and cohesivity. Higher G’ enables sustained tissue projection in the lower face where gravitational forces and mandibular muscle movement would deform softer fillers. The Vycross short-chain HA component allows more cross-linkers to bind at both chain ends, producing exceptional structural integrity and 18-24 month durability — necessary for the jawline and chin indications where re-treatment downtime is undesirable.
Juvederm Ultra 2 is Allergan’s lightest Hylacross-technology filler — 24 mg/mL cross-linked non-animal hyaluronic acid + 0.3% l…
View product →Juvederm Ultra 3 is Allergan’s medium-density Hylacross filler — 24 mg/mL cross-linked HA + 0.3% lidocaine produced by Streptoc…
View product →Monalisa Soft is GENOSS’s lightest variant — 24 mg/mL cross-linked HA + 0.3% lidocaine with the smallest particle size (200µm) …
View product →Browse our full range of HA dermal fillers, lip fillers, body fillers, and skin boosters for facial volume, contouring, and rejuvenation.
Browse category →Juvederm Volux with Lidocaine is a prescription medical device for use only by licensed aesthetic practitioners. Common reactions include injection-site bruising, swelling, redness, and tenderness — generally resolving within days. Deep placement (subcutaneous and supraperiosteal layers) involves heightened anatomical awareness of facial vasculature; practitioners require access to hyaluronidase for emergency dissolution. Like all hyaluronic acid dermal fillers, treatment carries rare but serious vascular complication risks. Contraindicated in patients with known hypersensitivity to hyaluronic acid or lidocaine, active skin infection at the treatment site, pregnancy, or breastfeeding. Full contraindications, vascular complication protocols, aftercare, and emergency guidance are detailed on the dermal filler safety page.
Read Full Dermal Filler Safety Information →Juvederm is a registered trademark of Allergan / AbbVie. Fillersfairy.com is a channel distributor and does not provide medical advice. This page is for informational purposes only and does not replace the manufacturer’s official Instructions for Use, which remains the authoritative source for clinical administration. Regulatory status varies by jurisdiction — buyers are responsible for verifying legal status before ordering. Last reviewed May 2026 against Allergan / AbbVie manufacturer documentation.
Your Premier Destination for High-Quality Aesthetic Products and Transformative Beauty Solutions
Sarah Jennings –
Was nervous about ordering fillers online until I saw FillersFairy’s FDA/CE certifications. The Volux syringe had a smooth plunger action much easier to control than expected. My chin projection looks natural, not that ‘overstuffed’ effect.